{{Rsnum
|rsid=7176005
|Gene=CYP19A1
|Chromosome=15
|position=51339082
|Orientation=plus
|GMAF=0.2415
|Gene_s=C14orf176
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{PMID Auto
|PMID=20048079
|Title=Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors
|OA=1
}}

{{PharmGKB
|RSID=rs7176005
|Name_s=
|Gene_s=CYP19A1
|Feature=NA
|Evidence=PubMed ID:20048079
|Annotation=Phenotype: This SNP, along with a second one in tight LD (rs6493497) was significantly associated, in a cohort of estrogen-receptor-positive patients with primary breast cancer larger than 3 cm, with change in aromatase activity before and after aromatase inhibitor neoadjuvant treatment . It was also associated, but not significantly so after adjustment for multiple testing, with change in estrone level and with pretreatment aromatase level. Study size: 45. Study population/ethnicity: Edinburgh female ER-positive patients, primary breast cancer larger than 3 cm. Significance metric(s): nominal p = 0.0063, p = 0.039 after adjustment for multiple testing. Type of association: PD; GN;FA. Second Phenotype: In a group of 200 women with early stage breast cancer, who were treated with 1 mg/day adjuvant anastrozole, this SNP was significantly associated with pre-drug and post-drug estradiol plasma concentrations after adjusting for plasma anastrozole concentrations. Study size: 200. Study population: women with early stage breast cancer (Mayo Clinic-M.D. Anderson pharmacogenomic study participants) . Significance metric(s):pre-drug p = 0.057; post-drug p = 0.0002. Type of association: PD; GN;FA
|Drugs=anastrozole; exemestane; letrozole
|Drug Classes=
|Diseases=Breast Neoplasms
|Curation Level=Curated
|PharmGKB Accession ID=PA165260358
}}

{{PMID Auto
|PMID=21939764
|Title=Effect of CYP19 rs6493497 and rs7176005 haplotype status on in vivo aromatase transcription, plasma and tissue estrogen levels in postmenopausal women
}}
{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs7176005
|overall_frequency_n=36
|overall_frequency_d=128
|overall_frequency=0.28125
|n_genomes=25
|n_genomes_annotated=0
|n_haplomes=31
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=24590773
|Title=Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial
}}

{{PMID Auto
|PMID=23408108
|Title=Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy.
|OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}